#### Values presented in table
* Method
* expected utility (u)
* assumed true hazard rate (HR)
* adjustment parameter (&lambda; or &alpha;<sub>CI</sub>)
* threshold value for the decision rule to go to phase III (HR<sub>go</sub>)
* total number of events for phase II (d<sub>2</sub>)
* total expected number of events for phase III (d<sub>3</sub>)
* total expected number of events in the program (d)
* total sample size for phase II (n<sub>2</sub>)
* total expected sample size for phase III (n<sub>3</sub>)
* total expected sample size in the program (n)
* probability to go to phase III (p<sub>go</sub>)
* probability of a successful program (sProg)
* probability of a successful program with small treatment effect (sProg1)
* probability of a successful program with medium treatment effect (sProg2)
* probability of a successful program with large treatment effect(sProg3)
* costs for phase II (K2)
* costs for phase III (K3)

and further input parameters.


#### References

IQWiG (2016). Allgemeine Methoden. Version 5.0, 10.07.2016, Technical Report. Available at https://www.iqwig.de/de/methoden/methodenpapier.3020.html, assessed last 15.05.19.

Kirby, S., Burke, J., Chuang-Stein, C., & Sin, C. (2012) Discounting phase 2 results when planning phase 3 clinical trials. <i>Pharmaceutical Statistics</i> 11(5), 373-385.

Schoenfeld, D. (1981). The asymptotic properties of nonparametric tests for comparing survival distributions. <i>Biometrika</i>, 68(1), 316-319.

Wang, S. J., Hung, H. M., & O'Neill, R. T. (2006). Adapting the sample size planning of a phase III trial based on phase II data. <i>Pharmaceutical Statistics</i> 5(2), 85-97.

#### Maintainer
Stella Preussler, Institute of Medical Biometry and Informatics, University of Heidelberg, email: Preussler@imbi.uni-heidelberg.de.

Beta version 0.3
